Lee YC, Hackett J, Frits M, Iannaccone CK, Shadick NA, Weinblatt ME, Segurado OG, Sasso EH. Multi-biomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia. Rheumatology. 2015. Accepted for publication.
Reiss WG, Devenport JN, Low JM, Wu G, Sasso EH. Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis. Rheumatol Int. 2015 May 31. [Epub ahead of print].
van Vollenhoven RF, Bolce R, Hambardzumyan K, Saevarsdottir S, Forslind K, Petersson IF, Sasso EH, Hwang CC, Segurado OG, Geborek P. Brief Report: Enhancement of Patient Recruitment in Rheumatoid Arthritis Clinical Trials Using a Multi-Biomarker Disease Activity Score as an Inclusion Criterion. Arthritis Rheumatol. 2015; 67:2855-60.
Maijer KI, Li W, Sasso EH, Gerlag DM, Defranoux NA, Tak PP. Does the multi-biomarker disease activity score have diagnostic value in early rheumatoid arthritis and unclassified arthritis? Ann Rheum Dis. 2015; 74(11):2097-9.
Li W, Sasso EH, van der Helm-van Mil AH, Huizinga TW. Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis. Rheumatology (Oxford). 2015 Sep 18. pii: kev341. PMID: 26385370.
Hambardzumyan K, Bolce R, Saevarsdottir S, Cruickshank SE, Sasso EH, Chernoff D, Forslind K, Petersson IF, Geborek P, van Vollenhoven RF. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial. Ann Rheum Dis. 2015 Jun; 1102-9.
Markusse IM, Dirven L, van den Broek M, Bijkerk C, Han KH, Ronday HK, Bolce R, Sasso EH, Kerstens PJ, Lems WF, Huizinga TW, Allaart CF. A multibiomarker disease activity score for rheumatoid arthritis predicts radiographic joint damage in the BeSt study. J Rheumatol. 2014;41:2114-9.
Li W, Sasso EH, Emerling D, Cavet G, Ford K. Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use. Curr Med Res Opin. 2013; 29:85-92.
Papp K, Menter A, Poulin Y, Gu Y, Sasso EH. Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study. J Eur Acad Dermatol Venerol. 2013;27:634-42.
Saurat J-H, Langley RG, Reich K, Unnebrink K, Sasso EH, Kampman. Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study. Br J Dermatol. 2011;165:399.
Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012;66:241-51.